Generic antiretroviral
PreclinicalSmall molecule
Generic antiretroviral is one of 44 small molecule programs targeting Psoriasis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
107 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Zasocitinib
TakedaPhase 3
D-2570
IInventisBio Co., Ltd
Phase 3
TAK-279
TakedaPhase 3
Ponvory
VVanda Pharmaceuticals
Phase 3
SYHX1901
CCSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
Vunakizumab (IL-17A Inhibitor)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
ICP-488
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
IDP-118 Lotion
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis1 trial
Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis
Completed·—·N/A·NCT04274595·8 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Generic antiretroviral. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details